Emergent's Vaccine Portfolio Aids Growth Amid Competition
Zacks Investment Research | Aug 28, 2019 02:28AM ET
On Aug 27, we issued an updated research report on Emergent BioSolutions Inc. (NYSE:EBS) .
Emergent’s newly acquired product Narcan (naloxone HCl) nasal spray has been performing well and made a significant contribution to the company’s top line during the first half of 2019. Narcan was added to Emergent’s portfolio following the acquisition of the privately held Adapt Pharma in October 2018.
Also, last October, Emergent acquired the specialty vaccine company PaxVax, which added two marketed vaccines, namely Vivotif (Typhoid Vaccine Live Oral Ty21a) and Vaxchora (Cholera Vaccine, Live, Oral) to its portfolio.
The buyouts of PaxVax and Adapt Pharma expanded Emergent’s presence in the public health threats market.
Shares of Emergent have plunged 31.6% so far this year, wider than the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.